Search - tctmd.com

Displaying 1 - 20 of 53

Sort: Relevancy | Date

Presentation TCT 2025

Non-Inferiority Trials – Bridge or Barrier to Patient-Centered Progress?

Presenter: Sanjay Kaul

October 27, 2025

Presentation TCT 2025

Not Much, We Need Stronger Evidence!

Presenter: Sanjay Kaul

October 26, 2025

Presentation NY Valves 2025

NO, Unblinded Patient-Reported Outcomes Are Simply Not Enough!

Presenter: Sanjay Kaul

June 26, 2025

Presentation TCT 2019

My Strategy for Interpreting (And Critiquing) Non-Inferiority Studies

Presenter: Sanjay Kaul

September 28, 2019

Presentation TCT 2018

The Perspective of a Non-Invasive Cardiologist Not So Fast!

Presenter: Sanjay Kaul

September 24, 2018

Presentation TCT 2018

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Otavio Berwanger, Peter Juni, Sanjay Kaul, Roxana Mehran, E. Magnus Ohman, Stuart J. Pocock, Giulio Stefanini

September 23, 2018

Presentation TCT 2018

Composite Endpoints: When Are They Valid and When Should They Be Discarded

Presenter: E. Magnus Ohman, Stuart J. Pocock, Sanjay Kaul

September 23, 2018

Presentation Controversies and Advances 2017

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Presenter: Sanjay Kaul

November 16, 2017

Presentation Controversies and Advances 2017

Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It?

Presenter: Sanjay Kaul

November 16, 2017

Presentation TCT 2017

Flash Debate: Surgery Remains the First Option in All Operable Patients With Bicuspid Aortic Stenosis!

Presenter: Gilles Dreyfus, Sanjay Kaul, Alfredo Trento

November 01, 2017

Presentation TCT 2017

Flash Debate: Enough Evidence Is Present to Justify TAVR in Select Patients With Bicuspid Aortic Stenosis!

Presenter: Gilles Dreyfus, Sanjay Kaul, John G. Webb

November 01, 2017

Presentation TCT 2017

Flash Debate: Surveillance and Prophylactic Treatment of Asymptomatic TAVR Thrombosis Is Not Currently Warranted!

Presenter: Gilles Dreyfus, Sanjay Kaul, Hendrik Treede

November 01, 2017

Presentation TCT 2017

Flash Debate: Valve Thrombosis After TAVR Is a Serious Concern That Deserves Detection and Management!

Presenter: Gilles Dreyfus, Sanjay Kaul, Raj Makkar

November 01, 2017

Presentation TCT 2017

Flash Debate: Based on Clinical Studies, Embolic Protection Devices Should Infrequently Be Used During TAVR

Presenter: Gilles Dreyfus, Sanjay Kaul, Duane S. Pinto

November 01, 2017

Presentation TCT 2017

Flash Debate: The Evidence and Clinical Need Justifies the Widespread Use of Embolic Protection During TAVR

Presenter: Gilles Dreyfus, Sanjay Kaul, Samir R. Kapadia

November 01, 2017

Presentation TCT 2017

Flash Debate: Bioresorbable Scaffolds Are Appropriate for Clinical Use in Suitable Patients With Optimal Technique!

Presenter: Sanjay Kaul, Tullio Palmerini, Robert-Jan van Geuns

November 01, 2017

Presentation TCT 2017

Flash Debate: Bioresorbable Scaffolds Should Rarely be Used Outside of Carefully Controlled Research Studies!

Presenter: Sanjay Kaul, Tullio Palmerini, Robert A. Byrne

November 01, 2017

Presentation TCT 2017

Flash Debate: If Anything, Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should be Downgraded Based on EXCEL and NOBLE!

Presenter: Sanjay Kaul, Tullio Palmerini, Jacek Legutko

November 01, 2017

Presentation TCT 2017

Flash Debate: Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should Be Upgraded to Class I Based on EXCEL and NOBLE!

Presenter: Sanjay Kaul, Tullio Palmerini, Evald H. Christiansen

November 01, 2017

Presentation TCT 2017

Flash Debate: Registry Data and Personal Experiences Are Strong Enough to Justify Frequent Use of IMPELLA in High-Risk PCI and Cardiogenic Shock!

Presenter: Sanjay Kaul, Tullio Palmerini, Dimitri Karmpaliotis

November 01, 2017

Advertisement

Non-Inferiority Trials – Bridge or Barrier to Patient-Centered Progress?

Not Much, We Need Stronger Evidence!

NO, Unblinded Patient-Reported Outcomes Are Simply Not Enough!

My Strategy for Interpreting (And Critiquing) Non-Inferiority Studies

The Perspective of a Non-Invasive Cardiologist Not So Fast!

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Composite Endpoints: When Are They Valid and When Should They Be Discarded

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It?

Flash Debate: Surgery Remains the First Option in All Operable Patients With Bicuspid Aortic Stenosis!

Flash Debate: Enough Evidence Is Present to Justify TAVR in Select Patients With Bicuspid Aortic Stenosis!

Flash Debate: Surveillance and Prophylactic Treatment of Asymptomatic TAVR Thrombosis Is Not Currently Warranted!

Flash Debate: Valve Thrombosis After TAVR Is a Serious Concern That Deserves Detection and Management!

Flash Debate: Based on Clinical Studies, Embolic Protection Devices Should Infrequently Be Used During TAVR

Flash Debate: The Evidence and Clinical Need Justifies the Widespread Use of Embolic Protection During TAVR

Flash Debate: Bioresorbable Scaffolds Are Appropriate for Clinical Use in Suitable Patients With Optimal Technique!

Flash Debate: Bioresorbable Scaffolds Should Rarely be Used Outside of Carefully Controlled Research Studies!

Flash Debate: If Anything, Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should be Downgraded Based on EXCEL and NOBLE!

Flash Debate: Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should Be Upgraded to Class I Based on EXCEL and NOBLE!

Flash Debate: Registry Data and Personal Experiences Are Strong Enough to Justify Frequent Use of IMPELLA in High-Risk PCI and Cardiogenic Shock!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content